ClinicalTrials.gg
Sign In
RecruitingNCT06974695CLEVERUpdated May 16, 2025

Identification of Predictive Factors for Failure of Cholangioscopy-assisted Lithotripsy in the Management of Complex Bile Duct Stones: a Retrospective Study

An observational study in Bile Duct Stones, sponsored by Central Hospital, Nancy, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Central Hospital, Nancy, France · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to optimize the management of complex biliary stones by identifying predictive factors for SpyGlass lithotripsy failure.

02

Conditions studied

  • Bile Duct Stones

Browse trials for

Keywords

  • Cholangioscopy
  • Spyglass
  • Failure
  • Complex bile duct stone
  • predictive factor
  • electrohydraulic lithotripsy
  • EHL
  • lithotripsy
  • ERCP
03

In context

Cholecystolithiasis

88 studies on the registry are indexed under Cholecystolithiasis; 17 are open to participants now.

This study's planned enrollment of 50 is below the median of 341 across 28 observational studies indexed under Cholecystolithiasis.

Browse Cholecystolithiasis studies →

Lead sponsor

Central Hospital, Nancy, France is the lead sponsor of 798 studies on the registry; 186 are open to participants now.

Browse Central Hospital, Nancy, France studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any adult patient who underwent cholangioscopy-guided lithotripsy for bile duct stones between January 1, 2018, and May 30, 2025

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any adult patient who underwent cholangioscopy-guided lithotripsy for bile duct stones between January 1, 2018, and May 30, 2025

Exclusion criteria

Exclusion Criteria:

  • Patient who objected to the collection of their data
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Predictive factors for failure of cholangioscopy lithotripsy in the management of complex bile duct stone

    Cholangioscopy-guided lithotripsy failure: defined as stone clearance requiring more than one lithotripsy session or surgical intervention

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • CHRU Brabois Vandoeuvre les Nancy
    Vandœuvre-lès-Nancy, Lorraine 54500, France
    Recruiting
    • Marion SCHAEFER, Hospital practionner · Contactm.schaefer@chru-nancy.fr
    • Raphaël Bouchès, Resident · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jun 2025, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 16, 2025
StartActual
May 1, 2025
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06974695
Lead sponsor
Central Hospital, Nancy, France
Responsible party
Marion SCHAEFER (Hospital practitioner, Central Hospital, Nancy, France) — Principal investigator
First posted
May 16, 2025
Start date
May 1, 2025
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
May 16, 2025

Study contacts

Marion SCHAEFER, hospital practitioner
Contact
m.schaefer@chru-nancy.fr
Marion SCHAEFER, hospital practitioner
study director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cholecystolithiasis →

Other studies from this sponsor

Central Hospital, Nancy, France →

Start the discussion